Bevacizumab, a humanized monoclonal VEGF-blocking antibody, improves progression-free survival in recurrent glioblastoma [10,11,12], although it is ineffective in extending overall survival in newly diagnosed glioblastoma patients [13,14,15,16]. The gene discussed is VEGFA; the disease is glioblastoma.